Rajiv Gandhi Cancer Institute and Research Centre
Delhi, India
7 recruiting
Showing 1–7 of 7 trials
Recruiting
Phase 3
A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
Colorectal Neoplasms
Janssen Research & Development, LLC1,000 enrolled238 locationsNCT06662786
Recruiting
Phase 3
A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy
Colorectal Neoplasms
Janssen Research & Development, LLC700 enrolled250 locationsNCT06750094
Recruiting
Phase 3
JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC
Carcinoma, Squamous Cell
Johnson & Johnson Enterprise Innovation Inc.500 enrolled193 locationsNCT04892173
Recruiting
Phase 3
A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib
MyelofibrosisAnemia
Takeda324 enrolled207 locationsNCT07623161
Recruiting
Phase 1
A Study Evaluating the Safety and Efficacy of AUR108 in Patients With Relapsed Advanced Lymphomas (ASHA-1)
Relapsed Advanced Lymphomas
Aurigene Discovery Technologies Limited40 enrolled27 locationsNCT05984147
Recruiting
Phase 3
Neoadjuvant Chemotherapy for Locally Advanced Gall Bladder Cancer : a Randomized Control Trial (NEOGB)
Gall Bladder Carcinoma
Rajiv Gandhi Cancer Institute & Research Center, India114 enrolled3 locationsNCT06712420
Recruiting
Phase 2
Dose Escalation Using Hypoxia-adjusted Radiotherapy
Head and Neck Squamous Cell Carcinoma
Rajiv Gandhi Cancer Institute & Research Center, India124 enrolled1 locationNCT06087614